Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPC3 | Q13507 | 1/20 | 0.75 |
| ▸ | TP53 | P04637 | 3/20 | 0.69 |
| ▸ | BCHE | P06276 | 2/20 | 0.69 |
| ▸ | ACHE | P22303 | 2/20 | 0.69 |
| ▸ | HTR3A | P46098 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | SORD | Q00796 | 1/20 | 0.51 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7848240 | 0.89 | TRPC3 (0.73) | TRPC3TP53BCHEACHEHTR3A | |
| SCHEMBL13450331 | 0.86 | TRPC3 (1.00) | TRPC3TP53BCHEACHEHTR3A | |
| SCHEMBL2674037 | 0.83 | BCHE (0.90) | TRPC3TP53BCHEACHEHTR3A | |
| SCHEMBL2676103 | 0.83 | BCHE (0.96) | TRPC3TP53BCHEACHEHTR3A | |
| SCHEMBL2674838 | 0.82 | TP53 (1.00) | TRPC3TP53BCHEACHEHTR3A | |
| SCHEMBL9369695 | 0.82 | TRPC3 (0.68) | TRPC3TP53BCHEACHEHTR3A | |
| SCHEMBL4713162 | 0.82 | TRPC3 (0.68) | TRPC3TP53BCHEACHEHTR3A | |
| SCHEMBL2241920 | 0.81 | BCHE (1.00) | TRPC3TP53BCHEACHEHTR3A | |
| SCHEMBL717865 | 0.81 | BCHE (1.00) | TRPC3TP53BCHEACHEHTR3A | |
| SCHEMBL531762 | 0.80 | HTR3A (1.00) | TRPC3TP53BCHEACHEHTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11332459-B2 | Benzimidazole derivatives and their uses | TEIJIN PHARMA LIMITED (JP) | 2022-05-17 | — | — | US | disclosed |
| US-20200308145-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USES | AMGEN INC. (US) | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308145-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USES | TRPC6, TRPV6, TRPM6 | TRPC3 9/4885TP53 4010/4885BCHE 3039/4885 |
| US-11332459-B2 | Benzimidazole derivatives and their uses | TRPC6, TRPV6, TRPM6 | TRPC3 9/4885TP53 4010/4885BCHE 3039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.